|
Pegademase bovine
resources
|
|
|
|
|
|
DRUG INFO
Pegademase bovine
Drug Name:
Pegademase bovine
Indication: For treatment of adenosine deaminase deficiency
Pharmacology: Used to replace deficient or inactive adenosine deaminase which leads to severe combined immunodeficiency disease (SCID). The enzyme is responsible for converting adensoine to inosine. In the absence of adenosine deaminase, the purine substrates adenosine, 2'-deoxyadenosine and their metabolites are actually toxic to lymphocytes thereby leading to diminished immune function.
Mechanism Of Action: Converts adenosine (toxic) to inosine (less toxic) by deamination. Also converts 2'-deoxyadenosine to 2’-deoxyinosine via deamination.
Drug Category: Enzyme replacement
Brand Names/Synonyms: Adenosine deaminase;Adenosine aminohydrolase; Adagen (Enzon Inc.)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: bovine adenosine deaminase (PEGylated)
Chemical Formula: C1821H2834N484O552S14
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00100
CAS Registry Number: 9026-93-1
|
|
|
|
|
|
Pegademase bovine News
(When available)
Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 9, 2006
dBusinessNews Newark (press release), ...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ...
Enzon Returns Rights to Transplantation Product to Fresenius ... Jan 6, 2006
Finanzen.net, ...of therapeutics totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R),ADAGEN(R), and ...
|
|
|
